The generic name for Vtama is tapinarof [1].
What is Tapinarof Used For?
Tapinarof is a topical treatment indicated for the treatment of plaque psoriasis in adults [1]. It is a non-steroidal aryl hydrocarbon receptor (AhR) agonist [2].
How Does Tapinarof Work?
Tapinarof works by activating the aryl hydrocarbon receptor (AhR) in the skin. This activation is believed to modulate inflammatory pathways, reduce cytokine production, and promote skin barrier repair [2].
When Did Tapinarof Receive FDA Approval?
Tapinarof received FDA approval in April 2022 [1].
What are the Potential Side Effects of Tapinarof?
Common side effects reported with tapinarof include upper respiratory tract infections, nasopharyngitis, and headache. Application site reactions such as folliculitis, contact dermatitis, and pruritus have also been observed [1].
What is the Pricing for Tapinarof?
Pricing information for tapinarof can vary. Patients may explore options such as coupons and savings programs through the manufacturer [3]. Information regarding drug pricing and patent exclusivity can often be found on specialized websites [4].
What are the Patent Expirations for Tapinarof?
Information on patent expirations for tapinarof is available through resources that track pharmaceutical patents. DrugPatentWatch.com is a source for such data [4].
What Other Treatments are Available for Plaque Psoriasis?
Other topical treatments for plaque psoriasis include corticosteroids, vitamin D analogs, calcineurin inhibitors, and retinoids. Systemic treatments, such as biologics and oral medications, are also available for moderate to severe cases [5].